| Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response A Lopez‐Girona, D Heintel, LH Zhang, D Mendy, S Gaidarova, H Brady, ... British journal of haematology 154 (3), 325-336, 2011 | 194 | 2011 |
| High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone D Heintel, A Rocci, H Ludwig, A Bolomsky, S Caltagirone, M Schreder, ... British journal of haematology 161 (5), 695-700, 2013 | 156 | 2013 |
| MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents A Bolomsky, M Vogler, MC Köse, CA Heckman, G Ehx, H Ludwig, J Caers Journal of hematology & oncology 13, 1-19, 2020 | 113 | 2020 |
| Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment A Bolomsky, K Schlangen, W Schreiner, N Zojer, H Ludwig Journal of Hematology & Oncology 9, 1-13, 2016 | 52 | 2016 |
| Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma A Bolomsky, D Hose, M Schreder, A Seckinger, S Lipp, B Klein, D Heintel, ... Journal of hematology & oncology 8, 1-14, 2015 | 32 | 2015 |
| Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro A Bolomsky, M Schreder, T Meißner, D Hose, H Ludwig, S Pfeifer, N Zojer Experimental hematology 42 (7), 516-525, 2014 | 31 | 2014 |
| Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma A Bolomsky, R Heusschen, K Schlangen, K Stangelberger, J Muller, ... Haematologica 103 (2), 325, 2018 | 26 | 2018 |
| Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma A Bolomsky, M Schreder, W Hübl, N Zojer, W Hilbe, H Ludwig Leukemia & lymphoma 57 (11), 2516-2525, 2016 | 22 | 2016 |
| The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of BMI‐1 as an essential … A Bolomsky, J Muller, K Stangelberger, M Lejeune, E Duray, H Breid, ... British journal of haematology 190 (6), 877-890, 2020 | 21 | 2020 |
| Molecular mechanisms, current management and next generation therapy in myeloma bone disease R Heusschen, J Muller, E Duray, N Withofs, A Bolomsky, F Baron, ... Leukemia & Lymphoma 59 (1), 14-28, 2018 | 21 | 2018 |
| Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease J Muller, A Bolomsky, S Dubois, E Duray, K Stangelberger, E Plougonven, ... Haematologica 103 (8), 1359, 2018 | 14 | 2018 |
| IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma A Bolomsky, W Hübl, S Spada, E Müldür, K Schlangen, D Heintel, A Rocci, ... American Journal of Hematology 92 (3), 269-278, 2017 | 12 | 2017 |
| Induction of indoleamine-2, 3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth S Pfeifer, M Schreder, A Bolomsky, S Graffi, D Fuchs, SS Sahota, ... Journal of cancer research and clinical oncology 138, 1821-1830, 2012 | 12 | 2012 |
| Treatment with HIV-protease inhibitor nelfinavir identifies membrane lipid composition and fluidity as a therapeutic target in advanced multiple myeloma L Besse, A Besse, SC Stolze, A Sobh, EA Zaal, AJ van der Ham, M Ruiz, ... Cancer research 81 (17), 4581-4593, 2021 | 10 | 2021 |
| Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma Y Yang, A Bolomsky, T Oellerich, P Chen, M Ceribelli, B Häupl, ... Nature communications 13 (1), 5469, 2022 | 8 | 2022 |
| Pathogenic signaling in multiple myeloma A Bolomsky, RM Young Seminars in oncology 49 (1), 27-40, 2022 | 8 | 2022 |
| Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma A Bolomsky, JJ Miettinen, A Malyutina, A Besse, J Huber, S Fellinger, ... Blood advances 5 (20), 4125-4139, 2021 | 7 | 2021 |
| Stratification for RRMM and risk-adapted therapy: sequencing of therapies in RRMM G Jeryczynski, A Bolomsky, H Agis, MT Krauth Cancers 13 (23), 5886, 2021 | 5 | 2021 |
| Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma A Schneller, N Zojer, A Bolomsky, H Ludwig haematologica 106 (9), 2516, 2021 | 5 | 2021 |
| Multiple myeloma drivers of high risk and response to stem cell transplantation identified by causal machine learning: out-of-cohort and experimental validation L Furchtgott, A Bolomsky, F Gruber, MK Samur, JJ Keats, J Yesil, ... Blood 130, 3029, 2017 | 5 | 2017 |
